Fulgent Genetics (FLGT) EPS (Weighted Average and Diluted) (2016 - 2026)
Fulgent Genetics' EPS (Weighted Average and Diluted) history spans 11 years, with the latest figure at -$0.8 for Q1 2026.
- On a quarterly basis, EPS (Weighted Average and Diluted) fell 116.22% to -$0.8 in Q1 2026 year-over-year; TTM through Mar 2026 was -$2.39, a 79.7% decrease, with the full-year FY2025 number at -$1.97, down 39.72% from a year prior.
- EPS (Weighted Average and Diluted) hit -$0.8 in Q1 2026 for Fulgent Genetics, down from -$0.76 in the prior quarter.
- Over the last five years, EPS (Weighted Average and Diluted) for FLGT hit a ceiling of $4.93 in Q1 2022 and a floor of -$4.3 in Q4 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.31 across 5 years, with a median of -$0.44 in 2023.
- Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 833.33% in 2023 and later surged 95.58% in 2024.
- Tracing FLGT's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.8 in 2022, then crashed by 437.5% to -$4.3 in 2023, then soared by 95.58% to -$0.19 in 2024, then crashed by 300.0% to -$0.76 in 2025, then decreased by 5.26% to -$0.8 in 2026.
- Business Quant data shows EPS (Weighted Average and Diluted) for FLGT at -$0.8 in Q1 2026, -$0.76 in Q4 2025, and -$0.21 in Q3 2025.